Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyroquilon is a synthetic small molecule fungicide belonging to the pyrroloquinoline class. It is primarily used as an agricultural chemical to control rice blast disease caused by the fungus Magnaporthe oryzae. Pyroquilon acts as a melanin synthesis inhibitor in fungi by binding to the naphthol pocket of fungal trihydroxynaphthalene reductase (THR), thereby disrupting melanin biosynthesis essential for fungal pathogenicity and survival. It is not approved for use within the European Union but has been marketed under various trade names in other regions. The compound has also been studied as a laboratory reagent and research tool for investigating fungal biology[2][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyroquilon.